EGFR and the complexity of receptor crosstalk in the cardiovascular system

Current Molecular Medicine

Volumn 13, Issue 1, 2013, Pages 3-12

  Sanchez Guerrero, E ^a   Jo, S R ^a   Chong, B H ^a   Khachigian, L M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cardiovascular biology; Cell signaling; Receptor crosstalk

Indexed keywords

AMPHIREGULIN; ANGIOTENSIN II; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CALCIUM ION; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIGEN; EPIREGULIN; G PROTEIN COUPLED RECEPTOR; INSULIN; INTERLEUKIN 1BETA; LYSOPHOSPHATIDIC ACID; MATRIX METALLOPROTEINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PHOSPHOLIPASE C GAMMA; PLATELET DERIVED GROWTH FACTOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; TENASCIN; THROMBIN; TRANSFORMING GROWTH FACTOR ALPHA; UNINDEXED DRUG; UROKINASE; EARLY GROWTH RESPONSE FACTOR 1; EGR1 PROTEIN, HUMAN;

ANCHORAGE INDEPENDENT GROWTH; ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROSIS; CARCINOGENESIS; CARDIOVASCULAR SYSTEM; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); GENE MUTATION; HEART DISEASE; HEART VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; MOLECULAR PATHOLOGY; NEOINTIMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RESTENOSIS; REVIEW; TRANSACTIVATION; TUMOR ASSOCIATED INFLAMMATION; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CARDIOVASCULAR DISEASE; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; APOPTOSIS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; EARLY GROWTH RESPONSE PROTEIN 1; HUMANS; MUSCLE, SMOOTH, VASCULAR; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84884403808     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652413804486313     Document Type: Review

References (126)

1. Schwartz SM. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 1997; 100: S87-9.
2. Campbell GR, Campbell JH. Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis. Exp Mol Pathol 1985; 42: 139-62.
3. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84: 767-801.
4. Ross R. The pathogenesis of atherosclerosis--an update. N Engl J Med 1986; 314: 488-500.
5. Santiago FS, Lowe HC, Day FL, Chesterman CN, Khachigian LM. Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. Am J Pathol 1999; 154: 937-44.
6. Nomoto A, Mutoh S, Hagihara H, Yamaguchi I. Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine. Atherosclerosis 1988; 72: 213-9.
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
8. Cho A, Graves J, Reidy MA. Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20: 2527-32.
9. Berasain C, Perugorria MJ, Latasa MU, et al. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) 2009; 234: 713-25.
10. Citri A, Yarden Y. EGF-ERBB signaling: towards the system level. Nat Rev Mol Cell Biol 2006; 7: 505-16.
11. Sibilia M, Kroismaryr R, Lichtenberger B, Natarajan A. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007; 75: 770-87.
12. Sanderson MP, Dempsey PJ, Dunbar AJ. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors 2006; 24: 121-36.
13. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-16.
14. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol 2009; 218: 460-6.
15. Bishayee A, Beguinot L, Bishayee S. Phosphorylation of tyrosine 992, 1068, and 1086 is required for conformational change of the human epidermal growth factor receptor cterminal tail. Mol Biol Cell 1999; 10: 525-36.
16. Johnson JL, Dwivedi A, Somerville M, George SJ, Newby AC. Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler Thromb Vasc Biol 2011; 31: e35-44.
17. Johnson TW, Wu YX, Herdeg C, et al. Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries. Arterioscler Thromb Vasc Biol 2005; 25: 754-9.
18. Takaguri A, Kimura K, Hinoki A, et al. A disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature. Hypertension 2011; 57: 841-5.
19. Gullick WJ. The Type 1 growth factor receptors and their ligands considered as a complex system. Endocr Relat Cancer 2001; 8: 75-82.
20. Johnson CG, Goldman JP, Gullick WJ. Simulating complex intracellular processes using object-oriented computational modelling. Prog Biophys Mol Biol 2004; 86: 379-406.
21. Okada S, Kao AW, Ceresa BP, et al. The 66-kDa Shc isoform is a negative regulator of the epidermal growth factor-stimulated mitogen-activated protein kinase pathway. J Biol Chem 1997; 272: 28042-9.
22. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999; 17: 259-69.
23. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-67.
24. Zwick E, Wallasch C, Ullrich A. HER2/neu: a target for breast cancer therapy. Breast Dis 2000; 11: 7-18.
25. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev 2001; 81: 999-1030.
26. Cheng CY, Kuo CT, Lin CC, Hsieh HL, Yang CM. IL-1beta induces expression of matrix metalloproteinase-9 and cell migration via a Src-dependent, growth factor receptor transactivation in A549 cells. Br J Pharmacol 2010; 160: 1595-610.
27. Raab G, Klagsbrun M. Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1997; 1333: F179-99.
28. Yamakana Y, Hayashi K, Komurasaki T. EGF family liganddependent phenotypic modulation of smooth muscle cells through EGF receptor. Biochem Biophys Res Commun 2001; 281: 373-7.
29. Mitsumata M, Gamou S, Shimizu N, Yoshida Y. Response of atherosclerotic intimal smooth muscle cells to epidermal growth factor in vitro. Arterioscler Thromb Vasc Biol 1994; 14: 1364-71.
30. Tamura R, Miyagawa J, Nishida M. Immunohistochemical localization of betacellulin, a member of epidermal growth factor family in atherosclerotic plaques from human aortae. Atheroscler 2001; 155: 413-23.
31. Lamb D, Modjtahedi H, Plant N, Ferns G. EGF mediates monocyte chemotaxis and macrophage proliferation and EGFR is expressed in atherosclerotic plaques. Atheroscl 2004; 176: 21-6.
32. Nanney L, Stoscheck C, King L. Characterization of binding and receptors for epidermal growth factor in smooth muscle. Cell Tissue Res 1988; 254: 125-32.
33. Russell KS, Stern DF, Polverini PJ, Bender JR. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Pathol 1999; 277: H2205-11.
34. Bagheri-Yarmand R, Vadlamudi RK, Wang RA, Mendelsohn J, Kumar R. VAscular endothelial growth factor upregulation via p21-activayed kinase 1 signalling regulates heregulin-b1-mediated angiogenesis. J Biol Chem 2000; 275: 39451-7.
35. Tamura R, Miyagawa J, Nishida M, et al. Immunohistochemical localization of Betacellulin, a member of epidermal growth factor family, in atherosclerotic plaques of human aorta. Atherosclerosis 2001; 155: 413-23.
36. Kato M, Inazu T, Kawai Y, et al. Amphiregulin is a potent mitogen for the vascular smooth muscle cell line, A7r5. Biochem Biophys Res Commun 2003; 301: 1109-15.
37. Toyoda H, Komurasaki T, Uchida D, Morimoto S. Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem J 1997; 326: 69-75.
38. Taylor DS, Cheng X, Pawlowski JE, Wallace AR, Ferrer P, Molloy CJ. Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc Natl Acad Sci USA 1999; 96: 1633-8.
39. Massague J, Pandiella A. Membrane-anchored growth factors. Annu Rev Biochem 1993; 62: 515-41.
40. Miyagawa J, Higashiyama S, Kawata S, et al. Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. J Clin Invest 1995; 95: 404-11.
41. Reape TJ, Wilson VJ, Kanczler JM, et al. Detection and cellular localization of heparin-binding epidermal growth factor-like growth factor mRNA and protein in human atherosclerotic tissue. J Mol Cell Cardiol 1997; 29: 1639-48.
42. Igura T, Kawata S, Miyagawa J, et al. Expression of heparinbinding epidermal growth factor-like growth factor in neointimal cells induced by balloon injury in rat carotid arteries. Arterioscler Thromb Vasc Biol 1996; 16: 1524-31.
43. Draude G, Hrboticky N, Lorenz RL. The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. Biochem Pharmacol 1999; 57: 383-6.
44. Kataoka H, Kume N, Miyamoto S, et al. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 1999; 99: 3110-7.
45. Chen M, Kakutani M, Minami M, et al. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 2000; 20: 1107-15.
46. Mukai E, Kume N, Hayashida K, et al. Heparin-binding EGFlike growth factor induces expression of lectin-like oxidized LDL receptor-1 in vascular smooth muscle cells. Atherosclerosis 2004; 176: 289-96.
47. Panutsopulos D, Arvanitis DL, Tsatsanis C, Papalambros E, Sigala F, Spandidos DA. Expression of heregulin in human coronary atherosclerotic lesions. J Vasc Res 2005; 42: 463-74.
48. Clement CM, Thomas LK, Mou Y, Croslan DR, Gibbons GH, Ford BD. Neuregulin-1 attenuates neointimal formation following vascular injury and inhibits the proliferation of vascular smooth muscle cells. J Vasc Res 2007; 44: 303-12.
49. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol 2001; 21: 6387-94.
50. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for inter-receptor signal transmission. Oncogene 2001; 20: 1594-600.
51. Schafer B, Gschwind A, Ullrich A. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 2004; 23: 991-9.
52. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 1991; 10: 2247-58.
53. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J 1997; 16: 7032-44.
54. Li J, Kim YN, Bertics PJ. Platelet-derived growth factorstimulated migration of murine fibroblasts is associated with epidermal growth factor receptor expression and tyrosine phosphorylation. J Biol Chem 2000; 275: 2951-8.
55. Majesky MW, Giachelli CM, Reidy MA, Schwartz SM. Rat carotid neointimal smooth muscle cells reexpress a developmentally regulated mRNA phenotype during repair of arterial injury. Circ Res 1992; 71: 759-68.
56. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402: 884-8.
57. Mifune M, Ohtsu H, Suzuki H, et al. G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem 2005; 280: 26592-9.
58. Ishida M, Ishida T, Thomas SM, Berk BC. Activation of extracellular signal-regulated kinases (ERK1/2) by angiotensin II is dependent on Src in vascular smooth muscle cells. Circ Res 1998; 82: 7-12.
59. Sabri A, Govindarajan G, Griffin TM, et al. Calcium-and protein kinase C-dependent activation of the tyrosine kinase PYK2 by angiotensin II in vascular smooth muscle. Circ Res 1998; 83: 841-51.
60. Li Y, Levesque LO, Anand-Srivastava MB. Epidermal growth factor receptor transactivation by endogenous vasoactive peptides contributes to hyperproliferation of vascular smooth muscle cells of SHR. Am J Physiol Heart Circ Physiol 2010; 299: H1959-67.
61. Gomez Sandoval YH, Levesque LO, Anand-Srivastava MB. Contribution of epidermal growth factor receptor transactivation in angiotensin II-induced enhanced expression of Gi protein and proliferation in A10 vascular smooth muscle cells. Can J Physiol Pharmacol 2009; 87: 1037-45.
62. Kalmes A, Vesti BR, Daum G, Abraham JA, Clowes AW. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. Circ Res 2000; 87: 92-8.
63. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 2001; 276: 7957-62.
64. Bakken AM, Protack CD, Roztocil E, Nicholl SM, Davies MG. Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism. J Vasc Surg 2009; 49: 1296-303.
65. Saito S, Frank GD, Motley ED, et al. Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivation. Biochem Biophys Res Commun 2002; 294: 1023-9.
66. Roztocil E, Nicholl SM, Davies MG. Insulin-induced epidermal growth factor activation in vascular smooth muscle cells is ADAM-dependent. Surgery 2008; 144: 245-51.
67. Jagadeesha DK, Takapoo M, Banfi B, Bhalla RC, Miller FJ, Jr. Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration. Cardiovasc Res 2012; 93: 406-13.
68. Hertig CM, Kubalak SW, Wang Y, Chien KR. Synergistic roles of neuregulin-1 and insulin-like growth factor-I in activation of the phosphatidylinositol 3-kinase pathway and cardiac chamber morphogenesis. J Biol Chem 1999; 274: 37362-9.
69. Werb Z, Yan Y. A cellular striptease act. Science 1998; 282: 1279-80.
70. Dempsey PJ, Garton K, Raines EW. Emerging roles of TACE as a key protease in ErbB ligand shedding. Mol Interv 2002; 2: 136-41.
71. Eguchi S, Frank GD, Mifune M, Inagami T. Metalloproteasedependent ErbB ligand shedding in mediating EGFR transactivation and vascular remodelling. Biochem Soc Trans 2003; 31: 1198-202.
72. Asakura M, Kitakaze M, Takashima S, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002; 8: 35-40.
73. Jones PL, Crack J, Rabinovitch M. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol 1997; 139: 279-93.
74. Millette E, Rauch BH, Defawe O, Kenagy RD, Daum G, Clowes AW. Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR-1 activation. Circ Res 2005; 96: 172-9.
75. Boerner JL, Biscardi JS, Silva CM, Parsons SJ. Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis. Mol Carcinog 2005; 44: 262-73.
76. Drube S, Stirnweiss J, Valkova C, Liebmann C. Ligandindependent and EGF recptor-supported transactivation: lesson form beta2-adrenergic receptor signalling. Cell Signal 2006; 18: 1633-46.
77. Chaturvedi D, Gao X, Cohen MS, Taunton J, Patel TB. Rapamycin induces transactivation of the EGFR and increases cell survival. Oncogene 2009; 28: 1187-96.
78. Graves LM, Han J, Earp HS, 3rd. Transactivation of the EGF receptor: is the PDGF receptor an unexpected accomplice? Mol Interv 2002; 2: 208-12.
79. Yamauchi T, Ueki K, Tobe K, et al. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone Nature 1997; 390: 91-6.
80. Shimizu H, Hirose Y, Goto S, et al. Indoxyl sulfate enchances angiotensin II signaling through upregulation of epidermal growth factor receptor expression in vascular smooth muscle cells. Life Sci 2012; 91: 172-7.
81. Lin CC, Lee CW, Chu TH, et al. Transactivation of Src, PDGF receptor, and Akt is involved in IL-1beta-induced ICAM-1 expression in A549 cells. J Cell Physiol 2007; 211: 771-80.
82. Wu CY, Hsieh HL, Sun CC, Tseng CP, Yang CM. IL-1 beta induces proMMP-9 expression via Src-dependent PDGFR/PI3K/Akt/p300 cascade in rat brain astrocytes. J Neurochem 2008; 105: 1499-512.
83. Wan YS, Wang ZQ, Voorhees J, Fisher G. EGF receptor crosstalks with cytokine receptors leading to the activation of c-Jun kinase in response to UV irradiation in human keratinocytes. Cell Signal 2001; 13: 139-44.
84. Tanida S, Joh T, Itoh K, et al. The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells. Gastroenterology 2004; 127: 559-69.
85. Aruoma OI, Halliwell B, Aeschbach R, Loligers J. Antioxidant and pro-oxidant properties of active rosemary constituents: carnosol and carnosic acid. Xenobiotica 1992; 22: 257-68.
86. Satoh T, Kosaka K, Itoh K, et al. Carnosic acid, a catecholtype electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. J Neurochem 2008; 104: 1116-31.
87. Tamaki Y, Tabuchi T, Takahashi T, Kosaka K, Satoh T. Activated glutathione metabolism participates in protective effects of carnosic acid against oxidative stress in neuronal HT22 cells. Planta Med 2010; 76: 683-8.
88. Wang T, Takikawa Y, Tabuchi T, et al. Carnosic acid (CA) prevents lipid accumulation in hepatocytes through the EGFR/MAPK pathway. J Gastroenterol 2012; 47: 805-13.
89. Wan Y, Belt A, Wang Z, Voorhees J, Fisher G. Transmodulation of epidermal growth factor receptor mediates IL-1 beta-induced MMP-1 expression in cultured human keratinocytes. Int J Mol Med 2001; 7: 329-34.
90. Petecchia L, Sabatini F, Usai C, Caci E, Varesio L, Rossi GA. Cytokines induce tight junction disassembly in airway cells via an EGFR-dependent MAPK/ERK1/2-pathway. Lab Invest 2012; 92: 1140-8.
91. Barbier D, Garcia-Verdugo I, Pothlichet J, et al. Influenza A induces the major secreted airway mucin MUC5AC in a protease-EGFR-ERK-Sp1 dependent pathway. Am J Respir Cell Mol Biol 2012; 47: 149-57.
92. Brusevold IJ, Aasrum M, Bryne M, Christoffersen T. Migration induced by epidermal and hepatocyte growth factors in oral squamous carcinoma cells in vitro: role of MEK/ERK, p38 and PI-3 kinase/Akt. J Oral Pathol Med 2012; 41: 547-58.
93. Mendelson K, Swendeman S, Saftig P, Blobel CP. Stimulation of platelet-derived growth factor receptor beta (PDGFRbeta) activates ADAM17 and promotes metalloproteinase-dependent cross-talk between the PDGFRbeta and epidermal growth factor receptor (EGFR) signaling pathways. J Biol Chem 2010; 285: 25024-32.
94. Nicholl SM, Roztocil E, Davies MG. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor. J Vasc Surg 2005; 41: 672-81.
95. Kiehne K, Brunke G, Meyer D, Harder J, Herzig KH. Oesophageal defensin expression during Candida infection and reflux disease. Scand J Gastroenterol 2005; 40: 501-7.
96. Pahl R, Brunke G, Steubesand N, et al. IL-1beta and ADAM17 are central regulators of beta-defensin expression in Candida esophagitis. Am J Physiol Gastrointest Liver Physiol 2011; 300: G547-53.
97. Gashler A, Sukhatme VP. Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog Nucleic Acid Res Mol Biol 1995; 50: 191-224.
98. Khachigian LM. Early growth response-1 in cardiovascular pathobiology. Circ Res 2006; 98: 186-91.
99. Khachigian LM, Anderson KR, Halnon NJ, et al. Egr-1 is activated in endothelial cells exposed to fluid shear stress and interacts with a novel shear-stress-response element in the PDGF A-chain promoter. Arterioscler Thromb Vasc Biol 1997; 17: 2280-6.
100. Khachigian LM, Lindner V, Williams AJ, Collins T. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science 1996; 271: 1427-31.
101. de Mestre AM, Rao S, Hornby JR, et al. Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. J Biol Chem 2005; 280: 35136-47.
102. Yan SF, Zou YS, Gao Y, et al. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci USA 1998; 95: 8298-303.
103. Wang B, Chen J, Santiago FS, et al. Phosphorylation and acetylation of histone H3 and autoregulation by early growth response 1 mediate interleukin 1beta induction of early growth response 1 transcription. Arterioscler Thromb Vasc Biol 2010; 30: 536-45.
104. Howe CL, Mayoral S, Rodriguez M. Activated microglia stimulate transcriptional changes in primary oligodendrocytes via IL-1beta. Neurobiol Dis 2006; 23: 731-9.
105. Sanchez-Guerrero E, Chen E, Kockx M, et al. IL-1beta Signals through the EGF Receptor and Activates Egr-1 through MMP-ADAM. PLoS One 2012; 7: e39811.
106. White KJ, Maffei VJ, Newton-West M, Swerlick RA. Irritant activation of epithelial cells is mediated via proteasedependent EGFR activation. J Invest Dermatol 2011; 131: 435-42.
107. Fuentes LQ, Reyes CE, Sarmiento JM, et al. Vasopressin up-regulates the expression of growth-related immediateearly genes via two distinct EGF receptor transactivation pathways. Cell Signal 2008; 20: 1642-50.
108. Keates S, Keates AC, Nath S, Peek RM, Jr, Kelly CP. Transactivation of the epidermal growth factor receptor by cag+ Helicobacter pylori induces upregulation of the early growth response gene Egr-1 in gastric epithelial cells. Gut 2005; 54: 1363-9.
109. Jones N, Agani FH. Hyperoxia induces Egr-1 expression through activation of extracellular signal-regulated kinase 1/2 pathway. J Cell Physiol 2003; 196: 326-33.
110. Hall KC, Blobel CP. Interleukin-1 stimulates ADAM17 through a mechanism independent of its cytoplasmic domain or phosphorylation at threonine 735. PLoS One 2012; 7: e31600.
111. Lalu MM, Cena J, Chowdhury R, Lam A, Schulz R. Matrix metalloproteinases contribute to endotoxin and interleukin-1beta induced vascular dysfunction. Br J Pharmacol 2006; 149: 31-42.
112. Wang Z, Kong L, Kang J, et al. Interleukin-lbeta induces migration of rat arterial smooth muscle cells through a mechanism involving increased matrix metalloproteinase-2 activity. J Surg Res 2011; 169: 328-36.
113. Amalinei C, Caruntu ID, Giusca SE, Balan RA. Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol 2010; 51: 215-28.
114. Schreier B, Döhler M, Rabe S, et al. Consequences of epidermal growth factor receptor (ErbB1) loss for vascular smooth muscle cells from mice with targeted deletion of ErbB1. Arterioscler Thromb Vasc Biol 2011; 31: 1643-52.
115. Rajagopalan V, Zucker IH, Jones JA, Carlson M, Ma YJ. Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction. Am J Physiol Heart Circ Physiol 2008; 295: H543-54.
116. Goishi K, Lee P, Davidson AJ, et al. Inhibition of zebrafish epidermal growth factor receptor activity results in cardiovascular defects. Mech Dev 2003; 120: 811-22.
117. Chan AK, Kalmes A, Hawkins S, Daum G, Clowes AW. Blockade of the epidermal growth factor receptor decreases intimal hyperplasia in balloon-injured rat carotid artery. J Vasc Surg 2003; 37: 644-9.
118. Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378: 394-8.
119. Perik PJ, de Vries EG, Gietema JA, et al. Serum HER2 levels are increased in patients with chronic heart failure. Eur J Heart Fail 2007; 9: 173-7.
120. Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995; 378: 390-4.
121. Iwamoto R, Yamazaki S, Asakura M, et al. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci USA 2003; 100: 3221-6.
122. Kagiyama S, Eguchi S, Frank GD, et al. Angiotensin IIinduced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 2002; 106: 909-12.
123. Berk BC. Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases. J Am Soc Nephrol 1999; 10 Suppl 11: S62-8.
124. Griendling KK, Ushio-Fukai M, Lassègue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 1997; 29: 366-73.
125. Day FL, Rafty LA, Chesterman CN, Khachigian LM. Angiotensin II (ATII)-inducible platelet-derived growth factor A-chain gene expression is p42/44 extracellular signalregulated kinase-1/2 and Egr-1-dependent and mediated via the ATII type 1 but not type 2 receptor. Induction by ATII antagonized by nitric oxide. J Biol Chem 1999; 274: 23726-33.
126. Buitrago M, Lorenz K, Maass AH, et al. The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nat Med 2005; 11: 837-44.